GlobeNewswire: AIM ImmunoTech Inc. Contains the last 10 of 406 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T19:54:59ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/28/2853964/0/en/AIM-ImmunoTech-to-Present-at-the-MedInvest-Biotech-Pharma-Investor-Conference.html?f=22&fvtc=4&fvtv=20744AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference2024-03-28T12:05:00Z<![CDATA[Live webcast presentation on Wednesday, April 3rd at 1:35 PM ET Live webcast presentation on Wednesday, April 3rd at 1:35 PM ET]]>https://www.globenewswire.com/news-release/2024/03/26/2852433/0/en/AIM-ImmunoTech-to-Discuss-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-April-2-2024-and-Host-Conference-Call-and-Webcast.html?f=22&fvtc=4&fvtv=20744AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast2024-03-26T13:05:00Z<![CDATA[OCALA, Fla., March 26, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) announced today that management will host a conference call and webcast to discuss the Company’s Q4/FY2023 operational and financial results on Tuesday, April 2, 2024, at 8:30 AM ET.]]>https://www.globenewswire.com/news-release/2024/03/25/2851692/0/en/AIM-ImmunoTech-Announces-Publication-of-Positive-Findings-from-a-Study-Evaluating-Ampligen-in-the-Treatment-of-Pancreatic-Cancer-in-the-Journal-Clinical-Cancer-Research.html?f=22&fvtc=4&fvtv=20744AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research2024-03-25T13:05:00Z<![CDATA[Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen Data demonstrate compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through Ampligen]]>Erasmus Medical CenterErasmus Medical Centerhttps://www.globenewswire.com/news-release/2024/03/22/2850954/0/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html?f=22&fvtc=4&fvtv=20744AIM ImmunoTech Announces Release of the Next CEO Corner Segment2024-03-22T12:55:00Z<![CDATA[OCALA, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, provided a corporate overview, a business outlook and discussed the AIM opportunity as part of the Virtual Investor Lunch Break series.]]>https://www.globenewswire.com/news-release/2024/03/20/2849440/0/en/AIM-ImmunoTech-Announces-Release-of-the-Next-CEO-Corner-Segment.html?f=22&fvtc=4&fvtv=20744AIM ImmunoTech Announces Release of the Next CEO Corner Segment2024-03-20T13:25:00Z<![CDATA[OCALA, Fla., March 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced the next CEO Corner segment has been published on the Company’s website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, provides an overview of Advanced Recurrent Ovarian Cancer and its unmet need, as well as the Company’s associated milestones with its clinical development program.]]>https://www.globenewswire.com/news-release/2024/03/15/2847048/0/en/AIM-ImmunoTech-to-Participate-in-the-Virtual-Investor-Lunch-Break-The-AIM-Opportunity.html?f=22&fvtc=4&fvtv=20744AIM ImmunoTech to Participate in the Virtual Investor Lunch Break: The AIM Opportunity2024-03-15T12:45:00Z<![CDATA[Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ET Live video webcast with Tom Equels, Chief Executive Officer of AIM ImmunoTech, on Wednesday, March 20th at 12:00 PM ET]]>https://www.globenewswire.com/news-release/2024/03/07/2842275/0/en/AIM-ImmunoTech-Announces-Launch-of-CEO-Corner-Platform.html?f=22&fvtc=4&fvtv=20744AIM ImmunoTech Announces Launch of CEO Corner Platform2024-03-07T13:45:00Z<![CDATA[CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress]]>AIM CEO CornerAIM CEO Cornerhttps://www.globenewswire.com/news-release/2024/02/29/2838011/0/en/AIM-ImmunoTech-Outlines-Recent-Progress-Across-Clinical-Development-Pipeline-and-Provides-Business-Update.html?f=22&fvtc=4&fvtv=20744AIM ImmunoTech Outlines Recent Progress Across Clinical Development Pipeline and Provides Business Update2024-02-29T13:45:00Z<![CDATA[Company continues progress across Ampligen® clinical development programs]]>https://www.globenewswire.com/news-release/2024/02/14/2829105/0/en/AIM-ImmunoTech-Announces-First-Subject-Dosed-in-the-Netherlands-for-Phase-1b-2-Study-Evaluating-Ampligen-rintatolimod-in-Combination-with-AstraZeneca-s-Imfinzi-durvalumab-for-the-T.html?f=22&fvtc=4&fvtv=20744AIM ImmunoTech Announces First Subject Dosed in the Netherlands for Phase 1b/2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi (durvalumab) for the Treatment of Pancreatic Cancer2024-02-14T13:55:00Z<![CDATA[Phase 1b portion of the study expected to be completed within six months Phase 1b portion of the study expected to be completed within six months]]>Erasmus Medical CenterErasmus Medical Centerhttps://www.globenewswire.com/news-release/2024/02/08/2826039/0/en/AIM-ImmunoTech-Reports-Positive-Topline-Results-from-Phase-2-Study-Evaluating-Ampligen-for-the-Treatment-of-Post-COVID-Conditions.html?f=22&fvtc=4&fvtv=20744AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions2024-02-08T13:50:00Z<![CDATA[Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions]]>AIM CEO Thomas K. EquelsAIM CEO Thomas K. Equels